Literature DB >> 21684011

Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study.

Mustafa Gulec1, Yavuz Selvi, Murat Boysan, Adem Aydin, Lutfullah Besiroglu, Mehmet Yucel Agargun.   

Abstract

BACKGROUND: Many patients who remit fully/partially or recover from an episode of major depression continue to suffer from sleep problems, mainly insomnia. Our study assesses the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent depressive relapse or recurrence in a group of full/partial remitters or recoverers.
METHOD: Sixty patients, 18 to 65 years of age, with current MDD defined using DSM-IV-TR criteria were participated in the study. They began a 24-week course of open-label acute plus continuation phase treatment mainly with SSRIs. Maintenance treatment was not planned for not affecting natural relapse or recurrence rates. All participants were evaluated by CGI-S, BDI, HAMD-17, PSQI, and ISI at weeks 0, 4, 12, 24, and 52.
RESULTS: Majority of the participants (83.33%) had subjective sleep disturbance, insomnia prior to relapse or recurrence. Repeated measures ANOVA was used to evaluate changes in scores of depression and sleep scales over time between recurred (N = 12) and non-recurred groups (N = 48). Differences between means were calculated with post hoc Bonferroni comparison test. The changes in scores of entire clinical scales over time between recurred and non-recurred groups were statistically significant. LIMITATIONS: The limitations of this study include the use of a relatively small, mostly young female sample and the lack of an objective sleep measure to corroborate self-report scales.
CONCLUSIONS: Early recognition and treatment of disturbances of the sleep-wake cycle may be important for treatment and prevention of recurrence of depression.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684011     DOI: 10.1016/j.jad.2011.05.056

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Is sleep disturbance linked to short- and long-term outcomes following treatments for recurrent depression?

Authors:  Elaine M Boland; Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  J Affect Disord       Date:  2019-10-31       Impact factor: 4.839

Review 2.  New hypothesis and treatment targets of depression: an integrated view of key findings.

Authors:  Shangli Cai; Shucai Huang; Wei Hao
Journal:  Neurosci Bull       Date:  2015-01-09       Impact factor: 5.203

3.  A decade's difference: 10-year change in insomnia symptom prevalence in Canada depends on sociodemographics and health status.

Authors:  Sheila N Garland; Hillary Rowe; Lily M Repa; Ken Fowler; Eric S Zhou; Michael A Grandner
Journal:  Sleep Health       Date:  2018-02-19

4.  Persistence of sleep problems in children with anxiety and attention deficit hyperactivity disorders.

Authors:  Berit Hjelde Hansen; Benedicte Skirbekk; Beate Oerbeck; Tore Wentzel-Larsen; Hanne Kristensen
Journal:  Child Psychiatry Hum Dev       Date:  2013-04

Review 5.  The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.

Authors:  Steven S Clevenger; Devvrat Malhotra; Jonathan Dang; Brigitte Vanle; Waguih William IsHak
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-01

6.  Characteristics of self-reported daily life note (LN) users in return-to-work judgment for workers on sick leave due to mental health conditions, and usefulness of the tool.

Authors:  Akira Kusumoto; Shigeyuki Kajiki; Yoshihisa Fujino; Katsuyuki Namba; Tomohisa Nagata; Masako Nagata; Akizumi Tsutsumi; Koji Mori
Journal:  Ind Health       Date:  2018-11-17       Impact factor: 2.179

7.  Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.

Authors:  Adam Savitz; Ewa Wajs; Yun Zhang; Haiyan Xu; Mila Etropolski; Michael E Thase; Wayne C Drevets
Journal:  Int J Neuropsychopharmacol       Date:  2021-12-08       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.